Scott Claunch

Scott Claunch is president of the TerraPower Isotopes® program, a division of TerraPower focused on the pursuit of next-generation therapeutic medical isotopes for Targeted Alpha Therapy (TAT) treatments. In this role, Claunch guides the business in the processing and delivery of select materials and grows the industry and innovator partnerships necessary to develop and commercialize TAT treatments to potentially eliminate many forms of cancer.

Prior to joining TerraPower, Claunch led the Global Nuclear Medicine Franchise at Lantheus Medical Imaging. He was responsible for commercial sales for all nuclear medicine products and pre-launch activities for Lantheus’ future portfolio in Positron Emission Tomography (PET). Additionally, he oversaw cyclotron operations used in the manufacture and distribution of radiopharmaceuticals globally. Previously, Claunch held various leadership positions in operations, change management, quality and sourcing at Option Care Health and Cardinal Health Nuclear Pharmacy Services.

Claunch remains active as a nuclear pharmacist and previously served as a board member for the Alzheimer’s Association, Central Ohio Chapter. He earned a Bachelor of Science degree in pharmacy, specializing in nuclear pharmacy, from the University of New Mexico.